| Serial Number | 97728299 |
| Word Mark | CAIDYA |
| Filing Date | Thursday, December 22, 2022 |
| Status | 807 - SU - NON-FINAL ACTION - MAILED |
| Status Date | Saturday, August 17, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, October 17, 2023 |
| Description of Mark | The mark consists of the stylized wording "CAIDYA" on the left with the stylized letters "C" and "A" intertwined together to form an infinity symbol, a vertical line in the middle and three Chinese characters on the right. |
| NOT AVAILABLE | The non-Latin characters in the mark transliterate to "KANG DI YA" and this has no meaning in a foreign language. |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Goods and Services | Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of pharmaceutical, medical, healthcare, and life sciences companies to assist them with clinical research, clinical trials and applications for drug, biologic and device approval; providing independent review of clinical trials for business purposes; Contract research organization (CRO) services, namely, business management in the field of clinical trials, namely, clinical data management |
| Translation of Words in Mark | The wording "CAIDYA" has no meaning in a foreign language. |
| Goods and Services | Providing independent review of clinical trials involving human subjects, namely, reviewing research protocols and related information to ensure protection of the rights and welfare of human subjects of research; regulatory compliance consulting in the pharmaceutical, medical, healthcare, and life sciences fields |
| Goods and Services | Contract research organization (CRO) services, namely, monitoring of clinical trials for drugs, biologics and devices of pharmaceutical, medical, healthcare, and life sciences companies for quality control purposes, and clinical trial project management in the nature of design and implementation of clinical trials and quality assurance for all major therapeutic areas, in particular gastroenterology, nephrology, urology, and oncology; consulting services in the field of scientific research in the nature of conducting clinical trials in the pharmaceutical industry, the biotechnology industry and the medical device and diagnostics industries; providing quality assurance services in the field of regulatory submissions to the FDA by life sciences companies to ensure validity and accuracy; product development for others, namely, providing implementation services relating to the development and validation of drugs, biologics and medical devices; Software as a service (SaaS) services featuring software for accessing, collecting, managing, tracking, analyzing, and reporting data and information on clinical trials; Contract research organization (CRO) services, namely, custom technical writing for others for non-advertising purposes in the nature of medical writing of clinical study protocols and reports; Contract research organization (CRO) services, namely, custom writing for others for non-advertising purposes in the nature of medical writing of clinical study protocols and reports for submission to regulatory authorities |
| International Class | 035 - Advertising; business management; business administration; office functions. |
| US Class Codes | 100, 101, 102 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, January 19, 2023 |
| Primary Code | 035 |
| First Use Anywhere Date | Thursday, August 31, 2023 |
| First Use In Commerce Date | Thursday, August 31, 2023 |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, January 19, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | Thursday, August 31, 2023 |
| First Use In Commerce Date | Thursday, August 31, 2023 |
| International Class | 045 - Legal services; security services for the protection of property and individuals; personal and social services rendered by others to meet the needs of individuals. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, January 19, 2023 |
| Primary Code | 045 |
| First Use Anywhere Date | Thursday, August 31, 2023 |
| First Use In Commerce Date | Thursday, August 31, 2023 |
| Party Name | Clinipace, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Morrisville, NC 27560 |
| Party Name | Clinipace, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Morrisville, NC 27560 |
| Event Date | Event Description |
| Monday, December 26, 2022 | NEW APPLICATION ENTERED |
| Thursday, January 19, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, January 20, 2023 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Friday, May 19, 2023 | ASSIGNED TO EXAMINER |
| Thursday, June 1, 2023 | NON-FINAL ACTION WRITTEN |
| Thursday, June 1, 2023 | NON-FINAL ACTION E-MAILED |
| Thursday, June 1, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, September 1, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, September 1, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, September 1, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, September 7, 2023 | EXAMINERS AMENDMENT -WRITTEN |
| Thursday, September 7, 2023 | EXAMINERS AMENDMENT E-MAILED |
| Thursday, September 7, 2023 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Thursday, September 7, 2023 | EXAMINER'S AMENDMENT ENTERED |
| Thursday, September 7, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, September 27, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, October 17, 2023 | PUBLISHED FOR OPPOSITION |
| Tuesday, October 17, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, December 12, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Wednesday, June 12, 2024 | USE AMENDMENT FILED |
| Wednesday, June 12, 2024 | TEAS STATEMENT OF USE RECEIVED |
| Thursday, August 1, 2024 | STATEMENT OF USE PROCESSING COMPLETE |
| Thursday, August 1, 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Saturday, August 17, 2024 | SU - NON-FINAL ACTION - WRITTEN |
| Saturday, August 17, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Saturday, August 17, 2024 | NON-FINAL ACTION E-MAILED |
| Friday, November 8, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Friday, November 8, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |